Cancer Chemotherapy and Pharmacology

, Volume 20, Issue 3, pp 265–266 | Cite as

High-dose VP-16 with intermediate-dose cytosine arabinoside in the treatment of relapsed acute nonlymphocytic leukemia

  • Hon Y. Chan
  • Frederick J. Meyers
  • Jerry P. Lewis
Short Communication VP-16, Cytosine Arabinoside, Nonlymphocytic Leukaemia


In a study of 11 adult patients with acute nonlymphocytic leukemia (ANLL), infusion therapy with high-dose VP-16 and intermediate-dose cytosine arabinoside was administered. Response was assessed with reference to bone marrow aspirations performed on days 1; 12, 13, or 14; and 21 of treatment. All 7 of the patients with ANLL in relapse achieved marrow hypoplasia, and 3 of them achieved complete response. LFTs were elevated in most patients but no evidence of hepatocellular necrosis was observed. It is concluded that the value of VP-16 in ANLL may have been underestimated in the past because of inadequate dosing.


Bone Marrow Leukemia Cancer Research Adult Patient Cytosine 



acute nonlymphocytic leukemia


chronic granulocytic leukemia






Ara-C, intermediate-dose Ara-C (500 mg/m2 for 12 doses)


Ara-C, high-dose Ara-C (3 g/m2 for 12 doses)


serum glutamic transaminase


lactic dehydrogenase


serum glutamic oxaloacetic transaminase


  1. 1.
    Herzig RH, Hillard ML, Wolff SN, Phillips GL, Herzig GP (1985) High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia. J Clin Oncol 3 (7): 992Google Scholar
  2. 2.
    Lewis JP (1985) Clinical trials of adult acute nonlymphocytic leukemia: evidence of progress. Cancer Treat Rev 12: 133–143Google Scholar
  3. 3.
    Postmus PE, Mulder NH, Sleijfer DT, Meinesz AF, Vriesendorp R, DeVries DGE (1984) High-dose etoposide for refractory malignancies: a phase I study. Cancer Treat Rep 68 (12): 1471Google Scholar
  4. 4.
    Preisler HD (1982) Treatment failure in AML. Blood Cells 8: 585–602Google Scholar
  5. 5.
    van Prooijen HC, Dekker AW, Punt K (1984) The use of intermediate dose cytosine arabinoside (ID Ara-C) in the treatment of acute non-lymphocytic leukaemia in relapse. Br J Haematol 57: 291–299Google Scholar

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • Hon Y. Chan
    • 1
  • Frederick J. Meyers
    • 1
  • Jerry P. Lewis
    • 1
  1. 1.Department of Internal Medicine, Division of Hematology and OncologyUniversity of California, Davis Medical CenterSacramentoUSA

Personalised recommendations